A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients With Advanced Solid Tumors With Liver Involvement

Alnylam Pharmaceuticals10 sites in 2 countries41 target enrollmentMarch 2009

ConditionsSolid Tumors

DrugsALN-VSP02

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: Solid Tumors
Sponsor: Alnylam Pharmaceuticals
Enrollment: 41
Locations: 10
Primary Endpoint: Safety and Tolerability of intravenous ALN-VSP02
Status: Completed
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.

Registry

clinicaltrials.gov

Start Date

March 2009

End Date

August 2011

Last Updated

14 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Alnylam Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients must have histologically or cytologically confirmed advanced solid tumors that have recurred or progressed following standard therapy, or that have not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
•Patient has measurable tumor in the liver
•At least 28 days have elapsed since the patient's prior systemic therapy, radiotherapy, or any major surgery
•Patient has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
•Patient has adequate hematologic, liver, and renal function
•Patient is seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV)
•Patient has a life expectancy \> 12 weeks

Exclusion Criteria

•Patient is receiving full-dose (therapeutic) anticoagulation therapy and/or aspirin \> 325 mg/day or other platelet inhibitory agents
•Patient has clinically significant cardiovascular disease or uncontrolled serious cardiac arrythmia
•Patient has known active brain or leptomeningeal metastases
•Patient has clinically significant cerebrovascular disease
•Patient has a seizure disorder not controlled on medication
•Patient has a known or suspected viral, parasitic or fungal infection
•Patient previously experienced a severe reaction to a liposomal product
•Patient has a known hypersensitivity to lipid products